Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

 Is this far enough along for your competent? doctor TO ENSURE HUMAN TESTING GETS DONE? You mean your doctor has no idea on contacting leadership to get necessary research accomplished? And s/he HASN'T BEEN FIRED YET?

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

• February 2025
• Translational Stroke Research

DOI:10.1007/s12975-025-01331-7

Authors:

Andrei Gresita

• University of Medicine and Pharmacy of Craiova

Dirk M Hermann

• University Hospital Essen

Ianis Kevyn Stefan Boboc

• University of Medicine and Pharmacy of Craiova

Thorsten R. Doeppner

Show all 7 authors

To read the full-text of this research, you can request a copy directly from the authors.

Abstract and Figures

Ischemic stroke, the second leading cause of death worldwide and the leading cause of long-term disabilities, presents a significant global health challenge, particularly in aging populations where the risk and severity of cerebrovascular events are significantly increased. The aftermath of stroke involves neuronal loss in the infarct core and reactive astrocyte proliferation, disrupting the neurovascular unit, especially in aged brains. Restoring the balance between neurons and non-neuronal cells within the perilesional area is crucial for post-stroke recovery. The aged post-stroke brain mounts a fulminant proliferative astroglial response, leading to gliotic scarring that prevents neural regeneration. While countless therapeutic techniques have been attempted for decades with limited success, alternative strategies aim to transform inhibitory gliotic tissue into an environment conducive to neuronal regeneration and axonal growth through genetic conversion of astrocytes into neurons. This concept gained momentum following discoveries that in vivo direct lineage reprogramming in the adult mammalian brain is a feasible strategy for reprogramming non-neuronal cells into neurons, circumventing the need for cell transplantation. Recent advancements in glial cell reprogramming, including transcription factor-based methods with factors like NeuroD1, Ascl1, and Neurogenin2, as well as small molecule-induced reprogramming and chemical induction, show promise in converting glial cells into functional neurons. These approaches leverage the brain’s intrinsic plasticity for neuronal replacement and circuit restoration. However, applying these genetic conversion therapies in the aged, post-stroke brain faces significant challenges, such as the hostile inflammatory environment and compromised regenerative capacity. There is a critical need for safe and efficient delivery methods, including viral and non-viral vectors, to ensure targeted and sustained expression of reprogramming factors. Moreover, addressing the translational gap between preclinical successes and clinical applications is essential, emphasizing the necessity for robust stroke models that replicate human pathophysiology. Ethical considerations and biosafety concerns are critically evaluated, particularly regarding the long-term effects and potential risks of genetic reprogramming. By integrating recent research findings, this comprehensive review provides an in-depth understanding of the current landscape and future prospects of genetic conversion therapy for ischemic stroke rehabilitation, highlighting the potential to enhance personalized stroke management and regenerative strategies through innovative approaches.

Schematic of in vivo cell reprogramming post-stroke, showing methods of reprogramming, conversion of reactive astrocytes into neurons, and integration into neural networks for functional recovery

… 

Figures - available from: Translational Stroke Research